Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/14—Antitussive agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• ORL-1 The nociceptin receptor ORL-1 has been shown to be involved with modulation of pain in animal models.
• ORL-1 (the nociceptin receptor) was discovered as an "orphan opioid-like receptor" i.e. a receptor whose ligand was unknown.
• the nociceptin receptor is a G protein coupled receptor. While highly related in structure to the three classical opioid receptors, i.e. the targets for traditional opioid analgesics, it is not activated by endogenous opioids. Similarly, endogenous opioids fail to activate the nociceptin receptor. Like the classical opioid receptors, the nociceptin receptor has a broad distribution in the central nervous system.
• nociceptin also known as Orphanin FQ (OFQ)
• OFQ Orphanin FQ
• nociceptin and its receptor are part of a newly discovered pathway involved in the perception of painful stimuli.
• nociceptin when administered intraspinally to rodents, is an analgesic.
• the efficacy of nociceptin is similar to that of endogenous opioid peptides.
• nociceptin acts as an anxiolytic when administered directly into the brain of rodents.
• nociceptin When tested in standard animals models of anxiety, the efficacy of nociceptin is similar to that seen with classical benzodiazapine anxiolytics. These data suggest that a small molecule agonist of the nociceptin receptor could have significant analgesic or anxiolytic activity. Additional recent data (Rizzi, et al, Life Sci.. 64, (1999), p. 157-
• nociceptin receptor agonists could be useful in the treatment of asthma.
• nociceptin reduces the rewarding properties of ethanol in msP alcohol preferring rats, suggesting that intervention of nociceptin could be useful in the treatment of alcohol abuse.
• Potent analgesic agents such as traditional opioids, e.g. morphine
• side-effects include tolerance, physical dependence, respiratory depression, sedation and a decrease in gastrointestinal motility.
• these side effects limit the dose of opioid that can be administered.
• Clinical data suggests that more than one-third of cancer patients have pain which is poorly controlled by present agents.
• Data obtained with nociceptin suggest the potential for advantages over opioids. When administered chronically to rodents, nociceptin, in contrast to morphine, showed no addiction liability. Additionally, chronic morphine treatment did not lead to a "cross-tolerance" to nociceptin, suggesting that these agents act via distinct pathways.
• ORL-1 receptor agonists are useful in the treatment of cough.
• ORL-1 receptor agonist in the treatment of cough.
• ORL-1 agonists any compound having ORL-1 agonist activity is claimed, but the following non-limiting list of compounds exemplifies ORL-1 agonists: a) a compound represented by the structural formula: or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond;
• X 1 is R5-(Ci-Ci 2 )alkyl, R 6 -(C 3 -C ⁇ 2 )cycloalkyl, R -aryl, R ⁇ - heteroaryl or R 10 -(C3-C7)heterocycloalkyl;
• Q is -CH 2 -, -O-, -S-, -SO-, -S0 2 - or -NR 17 -;
• R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen and (C-
• R 5 is 1 to 3 substituents independently selected from the group consisting of H, R 7 -aryl, R 6 -(C 3 -C 12 )cycloalkyl, R ⁇ -heteroaryl, R 10 -(C 3 - C 7 )heterocycloalkyl, -NR 19 R 2 o, -OR 13 an d -S(O) 0-2 R 13 ;
• R 6 is 1 to 3 substituents independently selected from the group consisting of H, (C 1 -C 6 )alkyl, R 7 -aryl, -NR 1 9R 20 , -OR 13 and -SR 13 ;
• R 7 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C- ⁇ -Ce)alkyl, R 2 5-aryl, (C 3 -C-
• R 8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C-
• R 9 is hydrogen, (C 1 -C 6 )aikyl, halo, -OR 19 , -NR 19 R20, -NHCN, - SR 19 or -(C 1 -C 6 )alkyl-NR 19 R20;
• R 10 is H, (C 1 -C 6 )alkyl, -OR 19 , -(C 1 -C 6 )alkyl-OR 19 , -NR 19 R20 or - (C 1 -C 6 )alkyl-NR 9 R20;
• R 11 is independently selected from the group consisting of H, R5-(C 1 -C 6 )alkyl, R 6 -(C 3 -C 12 )cycloalkyl, -(C 1 -C 6 )alkyl(C 3 -C 12 )cycloalkyl,
• R 2 is H, (C ⁇ -C 6 )alkyl, halo, -NO 2 , -CF 3 , -OCF 3 , -OR 19 , -(C C 6 )alkyl-OR 19 , -NR 9 R 2 0 or -(C 1 -C 6 )alkyl-NR 19 R20;
• R 13 is H, (C ⁇ -C 6 )alkyl, R 7 -aryl, -(C 1 -C 6 )alkyl-OR 19 , -(C ⁇ -C 6 )alkyl- NR 1 9R20; .(C ⁇ -C 6 )alkyl-SR 19 ; or aryl (C C 6 ) alkyl; R 14 and R 15 are independently selected from the group consisting
• R 16 and R 17 are independently selected from the group consisting of hydrogen, R 5 -(C ⁇ -C-6)alkyl, R 7 -aryl, (C 3 -C-
• R 19 and R 20 are independently selected from the group consisting of hydrogen, (C ⁇ -C-6)alkyl, (C 3 -C ⁇ 2 )cycloalkyl, aryl and aryl(C ⁇ -C6)alkyl;
• R 21 and R 22 are independently selected from the group consisting of hydrogen, (Ci-C ⁇ alkyl, (C 3 -C ⁇ 2 )cycloalkyl, (C 3 -C 12 )cycloalkyl(C ⁇ - C 6 )alkyl, (C 3 -C 7 )heterocycloalkyl, -(C ⁇ -C 6 )alkyl(C3-C 7 )-heterocycloalkyl, R 7 -aryl, R 7 -aryl(C 1 -C 6 )alkyl, R 8 -heteroaryl(CrCi 2 )alkyl, -(C 1 -C 6 )alkyl- OR 19 , -(d-CeJalkyl-NR ⁇ R 20 , -(C 1 -C 6 )alkyl-SR 19 , -(C 1 -C 6 )alkyl-NR 18 -(C 1 C 6 )alkyl-O-(C
• R 18 is hydrogen or (C ⁇ -Ce)alkyl
• Z is R 5 -(C ⁇ -C 12 )alkyl, R -aryl, R 8 -heteroaryl, R 6 -(C 3 -C 12 )cyclo- alkyl, R 1 0-(C 3 -C 7 )heterocycloalkyl, -CO 2 (C 1 -C 6 )alkyl, CN or - C(O)NR 19 R 2 0;
• Z 2 is hydrogen or Z 1 ;
• Z 3 is hydrogen or (C 1 -C 6 )alkyl; or Z 1 , Z 2 and Z 3 , together with the carbon to which they are attached, form the group
• ring A is a fused R 7 -phenyl or R 8 -heteroaryl ring;
• R 23 is 1 to 3 substituents independently selected from the group consisting of H, (C 1 -C 6 )alkyl, -OR 19 , -(C 1 -C 6 )alkyl-OR 19 , -NR 19 R ° and - (C 1 -C 6 )alkyl-NR 19 R20 ;
• R 24 is 1 to 3 substituents independently selected from the group consisting of R 23 , -CF 3 , -OCF 3 , NO 2 or halo, or R 24 substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;
• R 25 is 1-3 substituents independently selected from the group consisting of H, (C-
• R26 is independently selected from the group consisting of H, (C-
• R 27 is H, (C ⁇ -C 6 )alkyl, R -aryl(C ⁇ -C 6 )alkyl, or (C 3 -C 12 )cycloalkyl;
• R 28 is (C 1 -C 6 )alkyl, -(C ⁇ -C 6 )alkyl(C 3 -C 12 )cycloalkyl, R 7 -aryl, R 7 -aryl-(C 1 -C 6 )alkyl, R 8 -heteroaryl, -(C 1 -C 6 )alkyl-NR 9 R20 ⁇ -(C 1 -C 6 )alkyl-OR 1 9 or -(C 1 -C 6 )alkyl-SR 1 9.
• Preferred compounds of formula I are those wherein Z 1 and Z 2 are each R 7 -aryl, particularly R 7 -phenyl.
• Preferred R 7 substituents are (C-
• X 1 is R 7 -aryl, for example R 7 -phenyl
• X 2 is OH
• X 1 is R 7 -aryl
• X 2 is OH
• X 2 is -(CH 2 ) v OR 13
• v is 0
• R 13 is H) or -NC(O)R 28 , compounds wherein X 1 wherein R 12 is hydrogen and R 1 is (C 1 -C 6 )alkyl, -(C-
• X 1 and X 2 form a spiro group
• Z 1 is R 7 -aryl, preferably R 7 -phenyl
• Z 2 is C 4 hassle 12 -alkyl.
• R a and R 2a are, independently from each other, hydrogen, lower alkyl, lower alkoxy or halogen;
• R 3a is phenyl, optionally substituted by lower alkyl, CF 3 , lower alkoxy or halogen;
• R 4a is hydrogen, lower alkyl, lower alkenyl, -C(O)-lower alkyl, -C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylen-C(O)-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O- lower alkyl, lower alkyl-CH(OH)CF 3 , phenyl or benzyl;
• R 5a and R 6a are, independently from each other, hydrogen, phenyl, lower alkyl or di-lower alkyl or may form together a phenyl ring, and R 5a and one of R 1a or R 2a may form together a saturated or unsaturated 6 membered ring,
• a a is a 4-7 membered saturated ring which may contain a heteroatom such as O or S, or a pharmaceutically acceptable acid addition salt thereof.
• Preferred compounds of formula II include:
• R 1b is hydrogen, lower alkyl, halogen, lower alkoxy, CF 3 , lower alkyl-phenyl or (C 5.7 )-cycloalkyl;
• R 2b is hydrogen, lower alkyl, phenyl or lower alkyl-phenyl
• R 3 is hydrogen, lower alkyl, benzyl, lower alkyl-phenyl, lower alkyl- diphenyl, triazinyl, cyanomethyl, lower alkyl-piperidinyl, lower alkyl- naphthyl, (C 5 . 7 )-cycloalkyl, lower alkyl-(C 5 .
• R 4b is hydrogen, lower alkyl or nitrilo;
• a b is a ring system, consisting of (a) (C 5 - 15 )-cycloalkyl, which may be in addition to R 4b optionally substituted by lower alkyl, CF 3 , phenyl, (C 5 - 7 )-cycloalkyl, spiro-undecan- alkyl or by 2-norbornyl, or is one of the following groups
• R 5b and R 6b are hydrogen, lower alkyl, or taken together and with the carbon atoms to which they are attached form a phenyl ring;
• R 7b is hydrogen or lower alkyl;
• the dotted line represents an optional double bond and n is 1 to 4; or a pharmaceutically acceptable acid addition salt thereof.
• Preferred compounds of formula III include: 8-(decahydro-naphthalen-2-yl)-1 -phenyl-1 ,3,8-triaza-spiro[4.5]decan-4- one;
• R 3c is C C 7 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, phenyl- C C 5 alkyl, phenyl optionally substituted by 1 to 3 substituents independently selected from fluorine, C r C 3 alkyl and C C 3 alkoxy, or a heteroaryl group selected from furyl, theinyl, pyrrolyl and pyridyl, wherein said heteroaryl group is optionally substituted by 1 to 3 substituents independently selected from halo, C C 3 alkyl and C ⁇ C- 3 alkoxy, with the proviso that when both R 1c and R 2c are C C 4 alkyl, then R 3c is other than C r C 7 alkyl, C 2 -C 5 alkenyl and C 2 -C 5 alkynyl; R c is selected from
• R c is hydrogen or C C 6 alkyl
• the substituents to be attached to the aryl or heterocyclic moiety are independently selected from halo, hydroxy, carboxy, C r C 4 alkyl, C r C 4 alkoxy, C C 4 alkyl-CO-, amino(C r C 4 )alkyl-CO-, phenyl, benzyl, amino, mono- or di-(C C 4 alkyl)amino, hydrazino, azido, ureido, amidino and guanidino;
• R 5c is independently selected from halo, C,-C 3 alkyl, C C 3 alkoxy,
• Preferred compounds of formula IV include:
• Ar 1d is an optionally substituted aromatic carbon ring or heterocycle, wherein the optional substituents are independently selected from halo, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy and carboxyl;
• Cy d is an optionally substituted mono-, di- or tri-cyclic C 3 . 20 aliphatic carbon ring;
• R 1d is hydrogen, lower alkenyl, lower alkynyl, lower cycloalkyl, amino, lower alkylamino, di(lower alkyl)amino, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di(lower alkyl)carbamoyl or optionally substituted lower alkyl; and R 2d is hydrogen or lower alkyl. f) a compound disclosed in WO 99/48492 represented by the structural formula VI
• a e is an aryl or heterocyclyl ring
• B e is phenyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, oxazolyl or cyclohexenyl
• R 1e and R 2e are independently hydrogen, alkyl, hydroxyalkyl, amino, alkylamino or di-alkylamino;
• R 3e and R 4e are independently hydrogen, halo or alkyl;
• X e is hydrogen, halo, alkyl, alkoxyalkyl, alkenyl, amino, CN, or -(CH 2 ) me -E e -(CH 2 ) ne -G e ;
• G e is aryl, heterocyclyl, cycloalkyl or fused aryl, all optionally substituted by 1 -5 R 5e groups;
• R 5e is independently selected from halo, OH, alkyl, alkyl optionally substituted by alkoxy, alkoxyalkoxy, halo, OH or alkanoyloxy, alkoxy, alkoxyalkoxy, amino, alkylamino, di-alkylamino, NO 2 , CN, alkanoyl, alkanoyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl and phenyl; R 6e is hydrogen or aryl;
• R 7e is hydrogen, alkyl or alkoxycarbonyl; m e is 0-8; and n e is 1-4.
• a preferred compound of formula VI is: N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]benzamide.
• the disclosures of EP 856,514, EP921 ,125, WO 99/36421 , WO 98/54168 and WO 99/48492 are incorporated herein by reference.
• the compounds of formula I are described in greater detail below.
• the invention also relates to the use of an ORL-1 agonist for the manufacture of a medicament for use in treating cough.
• the invention relates to the use in the manufacture of a medicament for treating cough comprising the use of a compound of any of formuas I to VI.
• the invention also relates to a method of treating cough comprising administering to a mammal in need of such treatment an effective amount of an ORL-1 agonist.
• the invention relates to a method of treating cough comprising administering to a mammal in need of such treatment an effective amount of a compound of any of formulas I to VI.
• the invention relates to a method of treating cough comprising administering to a mammal in need of such treatment: (a) an effective amount of a nociceptin receptor ORL-1 agonist; and (b) an effective amount of one or more agents for treating cough, allergy or asthma symptoms selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukot ene inhibitors, H 3 inhibitors, ⁇ - adrenergic receptor agonists, xanthine derivatives, ⁇ -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK 1 7 NK 2 and NK 3 tachykinin receptor antagonists, and GABA B agonists.
• the invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a nociceptin receptor ORL-1 agonist and one or more agents selected from the group consisting of: antihistamines, 5- lipoxygenase inhibitors, leukothene inhibitors, H 3 inhibitors, ⁇ -adrenergic receptor agonists, xanthine derivatives, ⁇ -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK-i , NK 2 and NK 3 tachykinin receptor antagonists, and GABA ⁇ agonists.
• ORL-1 agonists for use in the combination and in the combined pharmaceutical composition are those represented in formulas I to VI.
• Figure 1 illustrates the effect in guinea pigs of Compounds A and B (see Example 12) compared to baclofen on capsaicin-induced cough.
• Figures 2A and 2B show changes in Tidal Volume after administration of Compound A or baclofen
• Figure 2C shows changes in frequency of breaths after administration of Compound A or baclofen.
• M + represents the molecular ion of the molecule in the mass spectrum and MH + represents the molecular ion plus hydrogen of the molecule in the mass spectrum;
• alkyl (including the alkyl portions of alkoxy, alkylamino and dialkylamino) represents straight and branched carbon chains containing from 1 to 12 carbon atoms or 1 to 6 carbon atoms; for example methyl, ethyl, propyl, iso-propyl, n-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; alkenyl represents an alkyl chain of 2 to 6 carbon atoms comprising one or two double bonds in the chain, e.g., vinyl, propenyl or butenyl; alkynyl represents an alkyl chain of 2 to 6 carbon atoms comprising one triple bond in the chain, e.g., ethynyl or propynyl; alkoxy represents an alkyl moiety covalently bonded to an adjacent structural
• aryl groups are phenyl, naphthyl and anthryl; arylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been substituted with one to three aryl groups; wherein aryl is as defined above; aryloxy represents an aryl group, as defined above, wherein said aryl group is covalently bonded to an adjacent structural element through an oxygen atom, for example, phenoxy; cycloalkyl represents saturated carbocyclic rings of from 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms; wherein R 6 -cycloalkyl means that any of the available substitutable carbon atoms in said cycloalkyl group is optionally and independently substituted, and wherein the cycloalkyl ring is substituted with 1-3 R 6 groups; cycloalkylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety
• heteroarylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heteroaryl groups, as defined above;
• heterocycloalkyl represents a saturated ring containing from 3 to 7 carbon atoms, preferably from 4 to 6 carbon atoms, interrupted by 1 to 3 heteroatoms selected from -O-, -S- and -NR 21 -, wherein R 21 is as defined above, and wherein optionally, said ring may contain one or two unsaturated bonds which do not impart aromatic character to the ring; and wherein any of the available substitutable carbon atoms in the ring may substituted, and wherein the heterocycloalkyl ring can be substituted with 1-3 R 10 groups;
• representative heterocycloalkyl groups include 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 1-, 2-, 3- or 4-piperidinyl, 2- or 3-pyrrolidinyl, 1-, 2- or 3-piperaz
• Certain compounds of formula I may exist in different stereoisomeric forms (e.g., enantiomers, diastereoisomers and atropisomers) .
• the invention contemplates all such stereoisomers both in pure form and in mixture, including racemic mixtures.
• Certain compounds used in the invention will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylgiucamine and the like. Certain basic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids.
• suitable acids for salt formation are hydrochloric, sulfu c, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art.
• the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
• the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
• the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention.
• X 1 ,X 2 -substituted piperidines are alkylated with Z 1 ,Z 2 ,Z 3 - substituted halomethanes in the presence of excess bases such as K2CO 3 and Et 3 N, in solvents such as DMF, THF or CH 3 CN, at room temperature or at elevated temperatures.
• X 1 ,X 2 -substituted piperidines are either commercially available or made by known procedures.
• 4-hydroxy-4-phenyl-piperidine can be converted to a 4-fl3oc-amino-4-phenylpiperidine according to the following reaction scheme, wherein Bn is benzyl, Ph is phenyl and fBoc is t-butoxycarbonyl:
• 4-phenyl-4-piperidinol is protected with a benzyl group and the resulting intermediate is then treated with Me 3 SiCN.
• the resultant amide is hydrolyzed with aqueous HCl in CH 3 OH to produce the 4-amino compound.
• the amino group is protected with ffioc and the N- benzyl group is removed by hydrogenolysis to produce the desired 4-amino-piperidine derivative.
• the 4-(protected)amino-piperidine then can be reacted with a Z ,Z 2 ,Z 3 -halomethane and the protecting group removed.
• the amine i.e., X 2 is -NH2
• X 2 is -NH2
• the amine of formula I can be reacted with a R 22 -carboxaldehyde in the presence of a mild reducing agent such as Na(OAc) 3 BH or with a compound of the formula R 22 -L, wherein L is a leaving group such as Cl or Br, in the presence of a base such as Et 3 N.
• An alternative method for preparing compounds of formula I wherein X 1 is R 7 -aryl and X 2 is OH involves alkylating a 4-pipehdone hydrochloride with a Z 1 ,Z 2 ,Z 3 -halomethane, then reacting the ketone with an appropriately substituted R 7 -phenylmagnesium bromide or with a compound of the formula X 1 -L 1 , wherein L 1 is Br or I, and n-butyl-lithium.
• X 1 ,X 2 -substituted compounds of formula I can be converted into other compounds of formula I by performing reactions well known in the art on the X 1 and/or X 2 substituents.
• a carboxaldehyde- substituted piperidine i.e., X 2 is -CHO
• X 2 is R 13 -O-CH2-, as shown in the following procedure for a compound of formula I wherein X 1 is phenyl, Z 1 and Z 2 are each phenyl, and R 1 , R 2 , R 3 and R 4 , and Z 3 are H :
• a cyano-substituted piperidine (i.e., X 2 is -CN) can be converted to a substituted piperidine wherein X 2 is R 21 R 22 N-CH2- or X 2 is R 28 C(O)NH-CH2-, as shown in the following procedure for a compound of formula I wherein X 1 is phenyl, R 2 , R 1 , R 2 , R 3 and R 4 , and Z 3 are H, and L is a leaving group such as Cl or Br:
• X 1 ,X 2 -substituted piperidine starting materials can be converted into other X 1 ,X 2 -substituted piperidines by similar procedures before reacting with the Z 1 ,Z 2 ,Z 3 -substituted halomethane.
• Pr is a N-protecting group
• Ph is phenyl and z is 1 -2.
• Z 1 ,Z 2 ,Z 3 -halomethyl derivatives wherein Z 1 and Z 2 are R 7 - phenyi are either commercially available or can be prepared using the procedure shown in the following reaction scheme:
• tetrahydrofuran THF
• EtOH ethanol
• MeOH methanol
• acetic acid HOAc or AcOH
• EtOAc ethyl acetate
• DMF N,N- dimethylformamide
• Et2 ⁇ diethyl ether
• Step 1 A solution of 4-piperidone monohydrate hydrochloride (5 g, 32.6 mmol) in CH 3 CN was alkylated using the procedure described in Example 1. Chromatography of the residue on silica (95:5 hexane/ EtOAc) gave the desired compound.
• Step 2 4-Methylphenylmagnesium bromide (0.5 M in THF, 1.75 ml, 0.87 mmol) was added to a solution of product of Step 1 (191 mg, 0.72 mmol) in THF dropwise at OC. The solution was stirred at 0 for 2h, quenched with ice-H2 ⁇ , extracted with EtOAc, washed with H2O and brine, dried, and concentrated. Chromatography of the residue on silica (95:5 hexane/EtOAc, 93:7 hexane/EtOAc) gave the title compound (0.091 g, 30%).
• 1 H NMR (CDCI3) ⁇ 7.5 (m, 6H, ArH), 7.3 (t, 4H, ArH), 7.2 (t, 4H,
• Step 1 4-Phenyl-4-piperidinecarboxaldehyde (1.0 g, 5.29 mM) was alkylated using the procedure of Example 1 , Step 1 , to obtain the desired product (1.69g, 90%).
• Step 2 A solution of the product from Stepl (3.0 g, 8.45 mmol) was cooled to 0°C and treated with NaBH 4 (1.0 g, 26.32 mmol).
• Step 3 The product of Step 2 was treated with NaH in DMF at 0°C for 0.5h. CH 3 I was added and reaction was warmed up to rt.
• Step 1 A solution of 4-cyano-4-phenylpiperidine hydrochloride (5.0 g, 22.4 mM) in DMF (30 ml) was treated with Et 3 N (7.20 ml, 47 mM) and bromodiphenylmethane (6.38 g, 25.80 mM) and stirred at rt under N2 for 20h. The reaction mixture was concentrated in vacuo and partitioned between EtOAc and H 2 0. The organic layer was washed with twice with water, then brine, and dried (MgSU4), filtered and concentrated. Chromatography (Si ⁇ 2, 19:1 hexane/EtOAc) gave 6.0 g (76%) of the desired product.
• 1 H NMR (CDCI3): ⁇ 2.21 (m, 4H), 2.49 (t, J 12.3Hz,
• Step 2 A solution of the product (6.0 g, 17 mM) of Step 1 in Et 2 O (40 ml) was cooled to 0°C and treated with a 1 M solution of of LAH (34.10 ml, 34 mM), dropwise, under N2, over 0.5 h. The reaction mixture was allowed to warm to rt and then refluxed for 4h. The reaction mixture was cooled to 0°C and treated with water (8 eq.). The reaction mixture was allowed to warm to rt and was stirred for 1 h. The resultant solid was filtered off and rinsed with Et2 ⁇ , and the filtrate was concentrated to yield 5.45 g
• Step 3 A solution of the product (0.2 g, 0.56 mM) of Step 2 in CH 2 CI 2 (3 ml) was treated with benzoyl chloride (0.078 ml, 0.673 mM) and pyridine (0.045g, 0.568 mM) at rt for 18 h under N2. The reaction mixture was concentrated, then partitioned between H2O and CH2CI2. The organic layer was washed with water (2x) and brine, then dried (MgSO4), filtered and concentrated. Chromatography (Si ⁇ 2, 3:1 hexane/EtOAc) gave 0.2 g (77%) of the desired product.
• Step 4 A solution of the product (0.075 g, 0.16 mM) of Step 3 in THF (3 ml) was cooled to 0°C with stirring. LAH (solid, 0.025 g, 0.65 mM) was added under N2 and stirring was continued for 0.25h. The reaction mixture was then refluxed for 5 h, then stirred at rt for 18h. The reaction mixture was cooled to 0°C and quenched with water (8 eq).
• Step 1 A solution of 4-phenyl-4-hydroxy piperidine (10.0 g, 56.4 mM) in DMF (60 ml) was treated with Et 3 N (8.28 ml, 59.2 mM) and benzyl bromide (7.37 ml, 62.10 mM) and stirred at rt under N 2 for 20 h.
• the reaction mixture was concentrated in vacuo, basified to pH 8 with saturated NaHCO 3 and partitioned between EtOAc and H2O. The organic layer was washed twice with water, then brine, and dried
• Step 2 To a mixture of the product (30.0 g, 0.112 mol) of Step 1 and (CH 3 ) 3 SiCN (59.94 ml, 0.448 mol), cooled to -15°C in an ethylene glycol/CO2 bath, under N2, is added glacial AcOH (47 ml) dropwise, while maintaining an internal temperature of -15°C. Concentrated H2SO4 (47 ml, 0.34 M) is added dropwise, with vigorous stirring, while maintaining an internal temperature of -15°C. The cooling bath was then removed and reaction mixture was stirred at rt for 18h. The reaction mixture was poured on ice and adjusted to pH 7 with a 50% NaOH solution while maintaining a temperature of 25°C.
• Step 3 The product of Step 2 (20 g, 67.9 mM) and 5% (w/w) concentrated HCl (aq)/CH3OH (350 ml) were stirred under N2 for 48 h.
• Step 4 The product of Step 3 (24.10 g, 71 mM), CH 2 CI 2 (300 ml), (tBoc) 2 O (17.0 g, 78.1 mM) and Et 3 N (14.37 g, 0.142 M) were combined and stirred under N2, at rt, for 18hrs.
• Step 5 The product of Step 4 (5.22 g, 14.2 mM), CH3OH (430 ml). Pd(OH) 2 /C (3.0 g) and NH4COOH (18.86 g, 0.298 M) were combined and refluxed under N2 for 8h. The reaction mixture was filtered using celite, washing with CH3OH. The combined filtrates were concentrated to produce (3.90 g, 97%) of the desired product.
• Step 6 The product of Step 5 (2.74 g, 9.91 mM), CH 3 CN (85 ml), Et 3 N
• Step 7 The product of Step 6 (4.6 g, 10 mM), 1 ,4-dioxane (38 ml) and 4 M HCl in 1 ,4-dioxane (25 ml, 101 mM) were combined and stirred at rt under N2 for 4 h. The mixture was concentrated and the residue was suspended in Et2 ⁇ and re-concentrated.
• Step 8 To a suspension of the product of Step 7 (0.3 g, 0.722 mM) in
• Step 1 Alkylate a solution of 4-(2-oxo-1-benzimidazolyl)-pipehdine in CH 3 CN using the procedure described in Step 1 of Example 1 to produce the desired compound.
• Step 2 Add NaH to a solution of 3-[1-(diphenylmethyl)-4-pipe dinyl]-1 ,3- dihydro-2H-benzimidazo-1-one (2.5 g, 6.6 mmol) in DMF (25 ml) and stir at rt for 1 h. Add n-butyl iodide to the mixture at rt and stir overnight. Quench with ice-H2 ⁇ , extract with EtOAc, wash with H2O and brine, dry (MgSO4) and concentrate. Chromatograph the residue on silica (1 :9
• Step 1 Alkylate a solution of 4-pipehdone monohydrate hydrochloride (880 mg, 5 mmol) in CH3CN with mandelonitrile (1 g, 7.51 mmol) using the procedure described in Example 9. Chromatography of the residue on silica followed by recrystallization (EtOAc) gives the desired compound (630 mg).
• Step 2 Add a solution of 2-methoxyphenylmagnesium bromide in THF (24 ml, 0.5 M, 11.85 mmol) to a solution of the product of Step 1 (330 mg, 1.185 mmol) in THF at 0C. Remove the ice-bath and stir the reaction mixture at reflux for 6 h. Quench the reaction with NH4CI (aq), extract with EtOAc, wash with brine, dry and concentrate. Chromatograph the residue (95:5, 9:1 hexane/EtOAc) to give the title compound (330 mg).
• Step 1 Alkylate a solution of 1 -phenyl-1 , 3, 8-triazaspiro[4,5]decan-4-one (0.5g) in CH3CN using the procedure described in Step 1 of Example 1 to produce desired compound.
• Step 2 Alkylate the product from Step 1 , 1-phenyl-8-(diphenylmethyl)- 1 ,3,8-triazaspiro[4,5]decan-4-one (0.4 g) with CH3I using the procedure described in Step 2 of Example 1 to produce the title compound (0.25 g).
• 1 H NMR (CDCI3) ⁇ 1.70 (d, 2H), 2.85 (m, 6H), 3.05(s, 3H), 4.50 (s, 1 H), 4.72 (s, 2H), 6.95 (t, 1 H), 7.05(d 2H), 7.20-7.60 (m, 12H).
• R 1 1 , Z 1 and Z 2 are as defined in the following table, wherein Ac is acetyl, Me is methyl and Et is ethyl::
• Nociceptin binding assay CHO cell membrane preparation expressing the ORL-1 receptor (2 mg) was incubated with varying concentrations of [ 125 l][Tyr 4 ]nociceptin (3- 500 pM) in a buffer containing 50 mM HEPES (pH7.4), 10 mM NaCl, 1 mM MgCl2, 2.5 mM CaCl2, 1 mg/ml bovine serum albumin and 0.025% bacitracin.
• assays were carried out in buffer 50 mM tris-HCI (pH 7.4), 1 mg/ml bovine serum alumbin and 0.025% bacitracin. Samples were incubated for 1 h at room temperature (22°C).
• Radiolabelled ligand bound to the membrane was harvested over GF/B filters presoaked in 0.1 % polyethyleneimine using a Brandell cell harvester and washed five times with 5 ml cold distilled water. Nonspecific binding was determined in parallel by similar assays performed in the presence of 1 ⁇ M nociceptin. All assay points were performed in duplicates of total and non-specific binding.
• Ki values were determined to be in the range of 0.6 to 3000 nM, with compounds having a Ki value less than 10 nM being preferred. Ki values for representative compounds of
• nociceptin agonist Compound A (0.3 - 10 mg/kg, p.o.) and Compound B (10 mg/kg, p.o.)
• COMPOUND A COMPOUND B were evaluated in capsaicin-induced cough in the guinea pig according to the methods of Bolser et al. British Journal of Pharmacology (1995) 114, 735-738. This model is a widely used method to evaluate the activity of potential antitussive drugs. Overnight fasted male Hartley guinea pigs (350-450 g, Charles River, Bioomington, MA, USA) were placed in a 12" x 14" transparent chamber. The animals were exposed to aerosolized capsaicin (300 ⁇ M, for 4 min) produced by a jet nebulizer (Puritan Bennett, Lenexa, KS, USA) to elicit the cough reflex.
• a jet nebulizer Puritan Bennett, Lenexa, KS, USA
• Each guinea pig was exposed only once to capsaicin.
• the number of coughs were detected by a microphone placed in the chamber and verified by a trained observer. The signal from the microphone was relayed to a polygraph which provided a record of the number of coughs.
• Either vehicle (methylcellulose 1 ml/kg, p.o.) or Compound A or Compound B were given 2 hours before aerosolized capsaicin.
• the antitussive activity of baclofen (3 mg/kg, p.o.) was also tested as a positive control. The results are summarized in the bar graph in Fig. 1.
• a head chamber was attached to the plethysmograph and air from a compressed gas source (21 % ⁇ 2 , balance N 2 ) was circulated through the head chamber for the duration of study. All respiratory measurements were made while the guinea pigs breathed this circulating air.
• volume signal from each animal was fed into a data acquisition/analysis system (Buxco Electronics, model XA) that calculated tidal volume and respiratory rate on a breath-by-breath basis. These signals were visually displayed on a monitor. Tidal volume and respiratory rate were recorded as an average value every minute.
• the guinea pigs were allowed to equilibrate in the plethysmograph for 30 min. Baseline measurements were obtained at the end of this 30 min period. The guinea pigs were then removed from the plethysmograph and orally dosed with Compound A from Example 12 (10 mg/kg, p.o.), baclofen (3 mg/kg, p.o.) or a methylcellulose vehicle placebo (2 ml/kg, p.o.). Immediately after dosing, the guinea pigs were placed into the plethysmograph, the head chamber and circulating air were reconnected and respiratory variables were measured at 30, 60, 90 and 120 min post treatment. This study was performed under ACUC protocol #960103.
• nociceptin receptor ORL-1 agonists exhibit anti-tussive activity, making them useful for suppressing coughing in mammals.
• the ORL-1 agonists decrease the severity and frequency of coughing.
• the coughing can be chronic, intractable or caused by a transient medical or environmental condition.
• Non-limiting examples of the causes for coughing are irritants, inflammatory diseases, influenza, asthma and upper respiratory diseases.
• the nociceptin receptor ORL-1 agonists may be administered along with one or more additional agents for treating cough, allergy or asthma symptoms selected from antihistamines, 5-lipoxygenase inhibitors, leukothene inhibitors, H 3 inhibitors, ⁇ -adrenergic receptor agonists, xanthine derivatives, ⁇ -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK-i , NK 2 and NK 3 tachykinin receptor antagonists, and GABA ⁇ agonists.
• the ORL-1 agonist can be administered in combination with an expectorant or an antihistamine, or with both an expectorant and an antihistamine.
• the combination preferably comprises 2 to 4 active agents.
• Non limitative examples of antihistamines include: astemizole, azatadine, azelastine, acrivastine, brompheniramine, certirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine (also known as SCH-34117), doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, equitazine, mianserin, noberastine, meclizine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, warmthlastine, trimeprazine and triprolidine.
• Non-limitative examples of histamine H3 receptor antagonists include: thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, UCL-1199 and clozapine.
• Other compounds can readily be evaluated to determine activity at H3 receptors by known methods, including the guinea pig brain membrane assay and the guinea pig neuronal ileum contraction assay, both of which are described in U.S. Patent 5,352,707.
• Another useful assay utilizes rat brain membranes and is described by West et al., "Identification of TW0-H3-
• leukothene inhibitor includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the action or activity of leukotrienes.
• Non-limitative examples of leukothene inhibitors include montelukast [R-(E)]-1 [[[1-[3-[2-(7-chloro-2-quinolinyl)-ethenyl] phenyl]-3[2-(1 -hydroxy-1 -methylethyl)phenyl]propyl]thio]methyl]cyclo- propaneacetic acid and its sodium salt, described in EP 0 480 717; 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2- propyl)phenyl)thio) methylcyclopropaneacetic acid, and its sodium salt, described in WO 97/28797 and U.S.
• Patent 5,270,324 1-(((1 (R)-3(3-(2- (2,3-dichlorothieno[3,2-b]pyhdin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1 -hydroxy- 1-methylethyl)phenyl) propyl)thio) methyl)cyclopropaneacetic acid, and its sodium salt, described in WO 97/28797 and U.S.
• 5-lipoxygenase inhibitor or "5-LO inhibitor” includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the enzymatic action of 5-lipoxygenase.
• Non-limitative examples of 5-lipoxygenase inhibitors include zileuton, docebenone, piripost, ICI-D2318, and ABT 761.
• Non-limitative examples of ⁇ -adrenergic receptor agonists include: albuterol, bitolterol, isoetha ne, mataproterenol, perbuterol, salmeterol, terbutaline, isoproterenol, ephedrine and epinephhne.
• Non-limitative examples of a xanthine derivative is theophylline.
• Non-limitative examples of ⁇ -adrenergic receptor agonists include arylalkylamines, (e.g., phenylpropanolamine and pseudephedrine), imidazoles (e.g., naphazoline, oxymetazoline, tetrahydrozoline, and xylometazoline), and cycloalkylamines (e.g., propylhexedrine).
• a non-limitative example of a mast cell stabilizer is nedocromil sodium.
• Non-limitative examples of anti-tussive agents include codeine, dextromethorphan, benzonatate, chlophedianol, and noscapine.
• a non-limitative example of an expectorant is guaifenesin.
• Non-limitative examples of decongestants are pseudoephed ne, phenylpropanolamine and phenylephrine.
• Non-limitative examples of NK-i , NK 2 and NK 3 tachykinin receptor antagonists include CP-99,994 and SR 48968.
• Non-limitatve examples of GABA B agonists include baclofen and
• inert, pharmaceutically acceptable carriers can be either solid or liquid.
• Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
• the powders and tablets may be comprised of from about 5 to about 70 percent active ingredient.
• Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose.
• Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
• a low melting wax such as a mixture of fatty acid glycehdes or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
• Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
• Liquid form preparations may also include solutions for intranasal administration.
• Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
• the compounds of the invention may also be deliverable transdermally.
• the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
• the compound is administered orally.
• the pharmaceutical preparation is in unit dosage form.
• the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
• the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
• the amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
• the amount of nociceptin receptor ORL-1 agonist in a unit dose is preferably from about 0.1 mg to 1000 mg, more preferably, from about 1 mg to 300 mg.
• a typical recommended dosage regimen is oral administration of from 1 mg to 2000 mg/day, preferably 1 to 1000 mg/day, in two to four divided doses. The compounds are non- toxic when administered within this dosage range.
• nociceptin receptor ORL-1 agonist and one or more additional agents are administered together, they are preferably administered in a combined dosage form (e.g., a single tablet), although they can be administered separately.
• the additional agents are administered in amounts effective to provide relief from cough, allergy or asthma symptoms, preferably from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 300 mg per unit dose.
• a typical recommended dosage regimen of the additional agent is from 1 mg to 2000 mg/day, preferably 1 to 1000 mg/day, in two to four divided doses.

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23415204

Family Applications (1)

Country Status (13)

Cited By (45)

Families Citing this family (40)

Citations (4)

Family Cites Families (33)

• 1999
  • 1999-07-26 US US09/359,771 patent/US6262066B1/en not_active Expired - Lifetime
• 2000
  • 2000-01-26 WO PCT/US2000/001853 patent/WO2001007050A1/en not_active Application Discontinuation
  • 2000-01-26 JP JP2001511934A patent/JP2003505420A/ja active Pending
  • 2000-01-26 BR BR0012801-5A patent/BR0012801A/pt not_active IP Right Cessation
  • 2000-01-26 AU AU26298/00A patent/AU2629800A/en not_active Abandoned
  • 2000-01-26 CN CN00813077A patent/CN1374865A/zh active Pending
  • 2000-01-26 EP EP00904560A patent/EP1200087A1/en not_active Withdrawn
  • 2000-01-26 MX MXPA02001033A patent/MXPA02001033A/es unknown
  • 2000-01-26 CA CA002379398A patent/CA2379398A1/en not_active Abandoned
  • 2000-01-26 HU HU0203458A patent/HUP0203458A3/hu unknown
• 2001
  • 2001-01-25 US US09/769,824 patent/US6455527B2/en not_active Expired - Lifetime
• 2002
  • 2002-01-11 ZA ZA200200275A patent/ZA200200275B/xx unknown
  • 2002-01-25 NO NO20020392A patent/NO20020392L/no not_active Application Discontinuation
  • 2002-05-08 HK HK02103499.8A patent/HK1042236A1/zh unknown
  • 2002-05-23 US US10/155,277 patent/US6716846B2/en not_active Expired - Fee Related
• 2004
  • 2004-01-21 US US10/761,977 patent/US7094784B2/en not_active Expired - Fee Related

Patent Citations (4)

Also Published As

Similar Documents

Legal Events